General Medicine and Primary Care

Host: Maurice Pickard, MD

Guest: Katherine Eban

Joining Dr. Maurice Pickard is award-winning journalist and author of Bottles of Lies: The Inside Story of the Generic Drug Boom Katherine Eban, who investigates the health concerns that are beginning to surface on a global scale due to the rise in generic drug use.

Host: Jennifer Caudle, DO

To gain more insights into how inflammatory bowel disease (IBD) affects our young patients, Dr. Jennifer Caudle connects with Caroline, a 12-year-old patient who was diagnosed with IBD at the age of 4, and her parents, Preston and Rachelle, about the challenges they face and the strategies and solutions available that can help children and teens like Caroline manage this condition.

Guest: Mary Beth Pfeiffer

With cases being reported in every state and across 80 countries, Lyme disease has become one of the fastest growing vector-borne illnesses in the world. But have you ever wondered how this global health threat came to be? That’s what journalist Mary Beth Pfeiffer investigates in her book, Lyme: The First Epidemic of Climate Change, and with the ReachMD team.

Host: Jennifer Caudle, DO

Guest: Stanley Green, MD

Fresh out of residency and hesitant to sign a long-term contract, Dr. Stanley Green was exploring other options for his career. That’s when he discovered locum tenens work, which might just hold the key to achieving his inspiring lifelong goal.

Host: Jennifer Caudle, DO

Guest: John Bielinski, PA

The rate of clinical burnout has increased throughout the years, but Dr. John Bielinski has the answers to help healthcare professionals liven up their careers and stay in a positive mindset.

Guest: Jennifer Caudle, DO

It’s an unfortunate reality that an increasing number of patients are refusing to get vaccinated—regardless of whether that’s the recommendation for themselves or their children. But luckily, there are ways you can talk to your patients about this, as Dr. Jennifer Caudle explains.

Host: Andrew Wilner, MD, FACP, FAAN

Hysteria is nothing new, but looking at how the spread of misinformation affects this disorder is a new concept. Providing an update to a blog he wrote back in 2012 entitled An Explanation for Mass Hysteria that was also featured in his book Bullets and Brains, Dr. Andrew Wilner dives into the contemporary problem of mass hysteria.

Host: Jennifer Caudle, DO

It can be easy to think of heat exhaustion and heatstroke as the same condition, but there’s a key difference between the two that we need to help our patients understand, especially during the warm summer months.

Host: Andrew Wilner, MD, FACP, FAAN

Guest: Colin Zhu, DO

Everyone loves eating, but what if we told you that eating specific foods could be used as a primary treatment? Dr. Andrew Wilner is joined by Dr. Colin Zhu to discuss the combination of culinary arts and the science of medicine along with how he educates the healthcare community about culinary medicine.

Host: Louis J Cohen, MD

Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Disease: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.

Siddharth Singh, MD, MS James Proudfoot, MS Ronghui Xu, PhDWilliam J Sandborn, MD

Background:

To assess whether obesity may affect natural history of inflammatory bowel diseases (IBD), we conducted an individual participant data (IPD) pooled analysis of placebo arms, using data from clinical trials of infliximab in IBD and using the Yale Open Data Access (YODA) Project.

Methods:

We obtained IPD from 4 placebo-controlled trials of infliximab in adults with IBD (ACCENT-I and ACCENT-II; ACT-1 and ACT-2). Patients were categorized into quartiles based on body mass index (BMI) or weight at time of trial entry. Primary outcome was clinical remission (Crohn’s disease activity index [CDAI]<150, Mayo Clinic Score <3); secondary outcomes were clinical response and mucosal healing. Using multivariable logistic regression analysis, we compared association between quartiles of BMI (or weight) and achieving remission, after adjusting for sex, smoking, disease activity, and concomitant prednisone or immunomodulators.

Results:

We included 575 placebo-treated patients (mean age 38 years, 51.6% males, 16% obese). Obesity was not associated with odds of achieving clinical …